SCHEMBL15399522

SCHEMBL15399522

c1ccc(C(c2ccccc2)(c2ccc3ccccc3c2)N2CCCC2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2B6 P20813 1/20 0.46
HRH3 Q9Y5N1 1/20 0.40
MCOLN3 Q8TDD5 2/20 0.39
TSHR P16473 1/20 0.39
PTPN1 P18031 2/20 0.39
KDM4E B2RXH2 2/20 0.39
KMT2A Q03164 2/20 0.38
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
HPGD P15428 1/20 0.36
RAB9A P51151 1/20 0.36
KIF11 P52732 1/20 0.35
HTR3A P46098 2/20 0.35
HTR3E A5X5Y0 1/20 0.35
HTR3B O95264 1/20 0.35
HTR5A P47898 1/20 0.35
HTR3D Q70Z44 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15399429 0.85 MEN1 (0.40) TSHRKDM4EKMT2AMEN1ALDH1A1
SCHEMBL2392136 0.84 CYP2B6 (0.59) CYP2B6TSHRKDM4EKMT2AMEN1
SCHEMBL2491599 0.82 CYP2B6 (0.63) CYP2B6TSHRKDM4EKMT2AMEN1
SCHEMBL19296941 0.82 CYP2B6 (0.63) CYP2B6TSHRKDM4EKMT2AMEN1
SCHEMBL27753492 0.80 CYP2B6 (0.54) CYP2B6TSHRKDM4EKMT2AMEN1
SCHEMBL2495637 0.78 ESR1 (0.53) CYP2B6TSHRKDM4EKMT2ASLC6A2
SCHEMBL2489520 0.76 CYP2B6 (0.56) CYP2B6HRH3TSHRKDM4EKMT2A
SCHEMBL27544718 0.76 ESR1 (0.52) CYP2B6KDM4EKMT2AMEN1HPGD
SCHEMBL12199488 0.76 CYP2B6 (0.56) CYP2B6HRH3TSHRKDM4EKMT2A
SCHEMBL12209773 0.76 CYP2B6 (0.51) CYP2B6KMT2AMEN1HPGDKIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871507-B2 Method of inhibiting apolipoprotein-E expression comprising administering a triarylmethyl amine compound CALIFORNIA STATE UNIVERSITY, FRESNO (US) 2014-10-28 US disclosed
US-20140080209-A1 METHOD OF INHIBITING APOLIPOPROTEIN-E EXPRESSION COMPRISING ADMINISTERING A TRIARYLMETHYL AMINE COMPOUND CALIFORNIA STATE UNIVERSITY FRESNO (US) 2014-03-20 US disclosed
US-8633195-B1 Method of inhibiting apolipoprotein-E expression comprising administering a triarylmethyl amine compound Fresno California State University (US) 2014-01-21 US disclosed
US-20140005196-A1 METHOD OF INHIBITING APOLIPOPROTEIN-E EXPRESSION COMPRISING ADMINISTERING A TRIARYLMETHYL AMINE COMPOUND California State University Fullerton (US) 2014-01-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140005196-A1 METHOD OF INHIBITING APOLIPOPROTEIN-E EXPRESSION COMPRISING ADMINISTERING A TRIARYLMETHYL AMINE COMPOUND APOB, APOL1, LDLR CYP2B6 339/4885HRH3 476/4885MCOLN3 4794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.